For research use only. Not for therapeutic Use.
Fludarabine phosphate（Cat No.:A001079）is an antineoplastic agent primarily used in the treatment of hematological malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. It is a prodrug of fludarabine, a nucleoside analog that interferes with DNA synthesis by inhibiting DNA polymerase and incorporating into DNA, leading to apoptosis in rapidly dividing cancer cells. Fludarabine phosphate enhances the efficacy of other chemotherapy agents and is often administered in combination therapies. Its ability to induce immunosuppression makes it effective in managing certain cancers, though it can also increase the risk of infections.
| Catalog Number | A001079 |
| CAS Number | 75607-67-9 |
| Synonyms | F-ara-A (NSC 312887) Phosphate |
| Molecular Formula | C10H13FN5O7P |
| Purity | ≥95% |
| Target | Apoptosis |
| Solubility | >17.6mg/mL in DMSO |
| Storage | 3 years -20C powder |
| IUPAC Name | [(2R,3S,4S,5R)-5-(6-amino-2-fluoropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate |
| InChI | InChI=1S/C10H13FN5O7P/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,14,15)(H2,19,20,21)/t3-,5-,6+,9-/m1/s1 |
| InChIKey | GIUYCYHIANZCFB-FJFJXFQQSA-N |
| SMILES | C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)F)N |
| Reference | </br>1:Using Gold Nanoparticles as Delivery Vehicles for Targeted Delivery of Chemotherapy Drug Fludarabine Phosphate to Treat Hematological Cancers. Song S, Hao Y, Yang X, Patra P, Chen J.J Nanosci Nanotechnol. 2016 Mar;16(3):2582-6. PMID: 27455673 </br>2:In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase. Sorscher EJ, Hong JS, Allan PW, Waud WR, Parker WB.Cancer Chemother Pharmacol. 2012 Aug;70(2):321-9. doi: 10.1007/s00280-012-1908-9. Epub 2012 Jul 4. PMID: 22760227 Free PMC Article</br>3:Successful treatment of cutaneous intravascular large B-cell lymphoma with fludarabine phosphate. Shan SJ, Chen J, Geng SL, Hong Y, Xu H, Guo Y, Wei H, Zhai M, Chen HD.Eur J Dermatol. 2010 May-Jun;20(3):408-9. doi: 10.1684/ejd.2010.0922. Epub 2010 Mar 9. No abstract available. PMID: 20215092 </br>4:Critical review of the determination process by the Japanese reviewing authority in approving the additional efficacy of fludarabine phosphate. Narimatsu H, Oiso G, Ono S, Kami M.J Clin Oncol. 2009 Dec 1;27(34):e236-8. doi: 10.1200/JCO.2009.23.9020. Epub 2009 Nov 2. No abstract available. PMID: 19884538 </br>5:Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. Yin W, Karyagina EV, Lundberg AS, Greenblatt DJ, Lister-James J.Biopharm Drug Dispos. 2010 Jan;31(1):72-81. doi: 10.1002/bdd.690. PMID: 19862681 </br>6:Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia. Walker S, Palmer S, Erhorn S, Brent S, Dyker A, Ferrie L, Horsley W, Macfarlane K, White S, Thomas S.Health Technol Assess. 2009 Jun;13 Suppl 1:35-40. doi: 10.3310/hta13suppl1/06. PMID: 19567212 Free Article</br>7:High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia. Cazin B, Divine M, Leprêtre S, Travade P, Tournilhac O, Delmer A, Jaubert J, Feugier P, Dreyfus B, Mahé B, Grosbois B, Maloisel F, Eghbali H, Dumontet C, Bénichou J, Guibon O, Leleu X, Leporrier M, Maloum K.Br J Haematol. 2008 Oct;143(1):54-9. doi: 10.1111/j.1365-2141.2008.07309.x. Epub 2008 Aug 15. PMID: 18710390 </br>8:Delivery of replication-competent retrovirus expressing Escherichia coli purine nucleoside phosphorylase increases the metabolism of the prodrug, fludarabine phosphate and suppresses the growth of bladder tumor xenografts. Kikuchi E, Menendez S, Ozu C, Ohori M, Cordon-Cardo C, Logg CR, Kasahara N, Bochner BH.Cancer Gene Ther. 2007 Mar;14(3):279-86. Epub 2007 Jan 12. PMID: 17218950 </br>9:Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin/’s lymphoma. Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, MacLennan K, Staab-Renner E, Kalmus J, Schott A, Teodorovic I, Negrouk A, van Glabbeke M, Marcus R.J Clin Oncol. 2006 Apr 1;24(10):1590-6. PMID: 16575010 </br>10:Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect. Dasgupta RK, Rule S, Johnson P, Davies J, Burnett A, Poynton C, Wilson K, Smith GM, Jackson G, Richardson C, Wareham E, Stars AC, Tollerfield SM, Morgan GJ.Bone Marrow Transplant. 2006 Mar;37(5):455-61. PMID: 16435017 |
